Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.
2.

Transforming the early drug development paradigm at the National Cancer Institute: The formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN).

Massett HA, Mishkin G, Moscow JA, Gravell AE, Steketee M, Kruhm M, Han SH, Barry B, Montello M, Zwiebel JA, Abrams JS, Doroshow JH, Ivy SP.

Clin Cancer Res. 2019 Aug 22. pii: clincanres.1754.2019. doi: 10.1158/1078-0432.CCR-19-1754. [Epub ahead of print]

PMID:
31439585
3.

Arthroscopic Surgical Stabilization of Glenohumeral Dislocations with Clavicular Graft and Remplissage.

Abrams JS.

JBJS Essent Surg Tech. 2019 Mar 27;9(1):e11. doi: 10.2106/JBJS.ST.17.00072. eCollection 2019 Mar 26.

4.

Simplified Technique for Superior Capsular Reconstruction Using an Acellular Dermal Allograft.

Laskovski JR, Boyd JA, Peterson EE, Abrams JS.

Arthrosc Tech. 2018 Oct 1;7(11):e1089-e1095. doi: 10.1016/j.eats.2018.07.002. eCollection 2018 Nov.

5.

Bias, Operational Bias, and Generalizability in Phase II/III Trials.

Freidlin B, Korn EL, Abrams JS.

J Clin Oncol. 2018 Jul 1;36(19):1902-1904. doi: 10.1200/JCO.2017.77.0479. Epub 2018 Apr 26. No abstract available.

6.

National Athletic Trainers' Association Position Statement: Evaluation, Management, and Outcomes of and Return-to- Play Criteria for Overhead Athletes With Superior Labral Anterior-Posterior Injuries.

Michener LA, Abrams JS, Bliven KCH, Falsone S, Laudner KG, McFarland EG, Tibone JE, Thigpen CA, Uhl TL.

J Athl Train. 2018 Mar;53(3):209-229. doi: 10.4085/1062-6050-59-16.

7.

Meeting the Challenge: The National Cancer Institute's Central Institutional Review Board for Multi-Site Research.

Massett HA, Hampp SL, Goldberg JL, Mooney M, Parreco LK, Minasian L, Montello M, Mishkin GE, Davis C, Abrams JS.

J Clin Oncol. 2018 Mar 10;36(8):819-824. doi: 10.1200/JCO.2017.76.9836. Epub 2018 Jan 31. Review.

8.
9.

Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study.

Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP.

J Shoulder Elbow Surg. 2018 Feb;27(2):242-251. doi: 10.1016/j.jse.2017.08.023. Epub 2017 Nov 20.

PMID:
29157898
10.

Arthroscopy Association of North America: Past, Present, and Future-2016 Presidential Address.

Abrams JS.

Arthroscopy. 2017 Sep;33(9):1611-1617. doi: 10.1016/j.arthro.2017.07.001. No abstract available.

PMID:
28865564
11.

A Randomized Controlled Study Comparing the National Cancer Institute's Original and Revised Consent Form Templates.

Masset HA, Hiser M, Atkinson NL, Brittle C, Bailey R, Adler J, Mishkin GE, Denicoff AM, Roach N, Good M, Burgess D, Patrick L, Mooney M, Abrams JS.

IRB. 2017 Sep-Oct;39(5):1-7.

PMID:
30703315
12.

Tissue Acquisition in Clinical Trials-Essential for Progress.

Ivy SP, Abrams JS.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djx003. No abstract available.

14.

Best Practices for Periarticular Infiltration With Liposomal Bupivacaine for the Management of Pain After Shoulder Surgery: Consensus Recommendation.

Joshi GP, Hawkins RJ, Frankle MA, Abrams JS.

J Surg Orthop Adv. Winter 2016;25(4):204-208. Review.

PMID:
28244860
15.

National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents.

Cristofaro JV, Ansher SS, Zwiebel JA, Ivy P, Conley B, Abrams JS, Doroshow JH.

Clin Pharmacol Ther. 2017 May;101(5):616-618. doi: 10.1002/cpt.585. Epub 2017 Mar 22. Review.

PMID:
27981567
16.

Immunogenicity of antigen-conjugated biodegradable polydiacetylene liposomes administered mucosally.

Abrams JS, Howe SE, Becerra N, Kohli P, Konjufca V.

J Biomed Mater Res A. 2017 Feb;105(2):557-565. doi: 10.1002/jbm.a.35938. Epub 2016 Nov 5.

PMID:
27750375
17.

Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.

Massett HA, Mishkin G, Rubinstein L, Ivy SP, Denicoff A, Godwin E, DiPiazza K, Bolognese J, Zwiebel JA, Abrams JS.

Clin Cancer Res. 2016 Nov 15;22(22):5408-5416. doi: 10.1158/1078-0432.CCR-16-0338. Epub 2016 Jul 11. Review.

18.

Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ.

Bladder Cancer. 2016 Apr 27;2(2):165-202.

19.

Arthroscopic Management of Anterior, Posterior, and Multidirectional Shoulder Instabilities.

Field LD, Ryu RK, Abrams JS, Provencher M.

Instr Course Lect. 2016;65:411-35.

PMID:
27049209
20.

Arthroscopic Implantation of a Bio-Inductive Collagen Scaffold for Treatment of an Articular-Sided Partial Rotator Cuff Tear.

Ryu RK, Ryu JH, Abrams JS, Savoie FH.

Arthrosc Tech. 2015 Sep 24;4(5):e483-5. doi: 10.1016/j.eats.2015.05.012. eCollection 2015 Oct.

21.

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.

Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354. Review.

22.

Genomic Profiling: Building a Continuum From Knowledge to Care.

Chen HX, Abrams JS.

JAMA Oncol. 2015 Jul;1(4):474-5. doi: 10.1001/jamaoncol.2015.1333. No abstract available.

PMID:
26181257
23.

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA.

Clin Cancer Res. 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13.

24.

Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.

Malik SM, Pazdur R, Abrams JS, Socinski MA, Sause WT, Harpole DH Jr, Welch JJ, Korn EL, Ullmann CD, Hirsch FR.

J Thorac Oncol. 2014 Oct;9(10):1443-8. doi: 10.1097/JTO.0000000000000314.

25.

Improving the protocol implementation process: the National Cancer Institute's response.

Abrams JS, Mooney M, Zwiebel J, Friedman S.

J Clin Oncol. 2014 Aug 10;32(23):2515-6. doi: 10.1200/JCO.2014.55.5912. Epub 2014 Jul 7. No abstract available.

PMID:
25002734
26.

Are we ready for the 10% solution?

Chen HX, Rubinstein LV, Shankar LK, Abrams JS.

Oncologist. 2014 May;19(5):439-40. doi: 10.1634/theoncologist.2014-0126. Epub 2014 Apr 22. No abstract available.

27.

New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials.

Freidlin B, Abrams JS, Korn EL.

J Comp Eff Res. 2013 Sep;2(5):469-81. doi: 10.2217/cer.13.50. Review.

PMID:
24236744
28.

Statistical and practical considerations for clinical evaluation of predictive biomarkers.

Polley MY, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM.

J Natl Cancer Inst. 2013 Nov 20;105(22):1677-83. doi: 10.1093/jnci/djt282. Epub 2013 Oct 17.

29.

Diagnosing segmental wedge fracture of the tibia before performing intramedullary nailing.

Gutowski C, Abrams JS, Gutowski WT.

Am J Orthop (Belle Mead NJ). 2013 Aug;42(8):369-71. Review.

PMID:
24078955
30.

An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology.

Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R.

Clin Trials. 2013 Oct;10(5):754-60. doi: 10.1177/1740774513493973. Epub 2013 Aug 9.

PMID:
23935162
31.

Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.

Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH.

J Natl Cancer Inst. 2013 Jul 3;105(13):954-9. doi: 10.1093/jnci/djt137. Epub 2013 Jun 17.

32.

Perspectives on humanism in medicine from the 2012 Edward J. III Excellence in Medicine honorees.

Abrams JS, Owen WF Jr, Brenner JC, Donlen J, Leone P, Carson JL, Slater EE.

MD Advis. 2012 Spring;5(2):4-9. No abstract available.

PMID:
22549607
33.

Bevacizumab in ovarian cancer.

Korn EL, Freidlin B, Abrams JS.

N Engl J Med. 2012 Mar 29;366(13):1256; author reply 1257-8. doi: 10.1056/NEJMc1201044. No abstract available.

PMID:
22455428
34.

Arthroscopic repair techniques for massive rotator cuff tears.

Abrams JS, Song FS.

Instr Course Lect. 2012;61:121-30.

PMID:
22301227
35.

Design issues in randomized phase II/III trials.

Korn EL, Freidlin B, Abrams JS, Halabi S.

J Clin Oncol. 2012 Feb 20;30(6):667-71. doi: 10.1200/JCO.2011.38.5732. Epub 2012 Jan 23.

36.

Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes?

McCaskill-Stevens W, Abrams JS.

J Natl Cancer Inst. 2011 Jul 20;103(14):1072-3. doi: 10.1093/jnci/djr239. Epub 2011 Jun 30. No abstract available.

37.

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

Korn EL, Freidlin B, Abrams JS.

J Clin Oncol. 2011 Jun 10;29(17):2439-42. doi: 10.1200/JCO.2011.34.6056. Epub 2011 May 9. Review.

38.

Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer Institute.

Trimble EL, Abrams JS, Ansher SS, Smith MA, Zwiebel JA, Tomaszewski JE.

Future Med Chem. 2010 Apr;2(4):555-9. doi: 10.4155/fmc.10.11. No abstract available. Erratum in: Future Med Chem. 2010 May;2(5):902.

39.

Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007.

Korn EL, Freidlin B, Mooney M, Abrams JS.

J Clin Oncol. 2010 Dec 10;28(35):5197-201. doi: 10.1200/JCO.2010.31.5382. Epub 2010 Nov 8.

40.

Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.

Kaiser LD, Melemed AS, Preston AJ, Chaudri Ross HA, Niedzwiecki D, Fyfe GA, Gough JM, Bushnell WD, Stephens CL, Mace MK, Abrams JS, Schilsky RL.

J Clin Oncol. 2010 Dec 1;28(34):5046-53. doi: 10.1200/JCO.2010.29.6608. Epub 2010 Oct 4.

41.

Management of the failed rotator cuff surgery: causation and management.

Abrams JS.

Sports Med Arthrosc Rev. 2010 Sep;18(3):188-97. doi: 10.1097/JSA.0b013e3181eb6cc1. Review.

PMID:
20711051
42.

Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.

Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R.

Cancer Invest. 2010 Nov;28(9):963-8. doi: 10.3109/07357907.2010.496759.

43.

Jeffrey S. Abrams, MD, on "Pathoanatomy of first-time, traumatic, anterior glenohumeral subluxation events" by Lieutenant Colonel Brett D. Owens, MD, et al.

Abrams JS.

J Bone Joint Surg Am. 2010 Jul 7;92(7):e5. doi: 10.2106/JBJS.J.00736. No abstract available.

PMID:
20595561
44.

Arthroscopic management of shoulder instabilities: anterior, posterior, and multidirectional.

Abrams JS, Bradley JP, Angelo RL, Burks R.

Instr Course Lect. 2010;59:141-55. Review.

PMID:
20415377
45.

Strengthening accrual to cancer clinical trials.

Trimble EL, Denicoff AM, Abrams JS.

Gynecol Oncol. 2010 Mar;116(3):291-2. doi: 10.1016/j.ygyno.2010.01.015. No abstract available.

PMID:
20152512
46.

NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.

Minig L, Trimble EL, Birrer MJ, Kim KY, Takebe N, Abrams JS.

Gynecol Oncol. 2010 Feb;116(2):177-80. doi: 10.1016/j.ygyno.2009.10.046. Epub 2009 Nov 3. Review.

PMID:
19889449
47.

Improving cancer outcomes through international collaboration in academic cancer treatment trials.

Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacombe D, Parmar M, Seibel N, Shankar L, Swart AM, Therasse P, Vikram B, von Frenckell R, Friedlander M, Fujiwara K, Kaplan RS, Meunier F.

J Clin Oncol. 2009 Oct 20;27(30):5109-14. doi: 10.1200/JCO.2009.22.5771. Epub 2009 Aug 31. Review.

48.

Treatment success in cancer.

Korn EL, Mooney MM, Abrams JS.

Arch Intern Med. 2008 Oct 27;168(19):2173; author reply 2173-4. doi: 10.1001/archinte.168.19.2173-a. No abstract available.

PMID:
18955658
49.

Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.

Korn EL, Hunsberger S, Freidlin B, Smith MA, Abrams JS.

Clin Trials. 2008;5(4):364-5; author reply 365-6. doi: 10.1177/1740774508094749. No abstract available.

PMID:
18697851
50.

Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies.

Abrams JS.

Curr Protoc Immunol. 2001 May;Chapter 6:Unit 6.20. doi: 10.1002/0471142735.im0620s13.

PMID:
18432811

Supplemental Content

Loading ...
Support Center